Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Should Present Its Own Proposal to Design Envisioned Mixed Care System: Panel Chair
April 28, 2014
- PMDA’s Preliminary Meetings, Face-to-Face Counseling Rise in FY2013
April 28, 2014
- Chuikyo Healthcare Provider Rep Vexed by Health Minister Proposal on Use of Drug Cost-Effective Assessment
April 25, 2014
- JMA Veep Nakagawa Fumes at Industry, Says “Application Lag” Elicited New Mixed Care Proposal
April 25, 2014
- Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
- LDP Study Group to Call for Expansion of R&D Tax Credit System, Oppose Annual NHI Price Cuts
April 24, 2014
- PAFSC’s Second Committee to Discuss Janssen, Sanofi Prostate Cancer Drugs on April 30
April 23, 2014
- Public Knowledge-Based Applications Appropriate for Propranolol, Levonorgestrel: Panel
April 23, 2014
- Health Minister Wary about Annual Drug Price Cuts, but Aso, Amari Give Backing
April 23, 2014
- Min. Tamura Positive about Mixed Care Discussions with Govt Panel
April 22, 2014
- MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
April 21, 2014
- DPJ Member Nagatsuma Asks MHLW to Consider Criminal Complaint over SIGN Trial
April 18, 2014
- New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
April 18, 2014
- Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
April 18, 2014
- Govt Deregulation Panel Tenders Prerequisites for Envisaged Mixed Care System
April 17, 2014
- MHLW to Mull Applying Mixed Care Scheme to Low Cost-Effective Drugs: Minister
April 17, 2014
- Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
- PAFSC’s First Committee to Review Canagliflozin, Japan’s 5th SGLT-2 Inhibitor
April 15, 2014
- Pharma Leaders Push Abe Govt to Permanently Introduce Key Premium, R&D Tax Credit
April 15, 2014
- MHLW Panel on Counterfeit Drugs Holds First Meeting
April 14, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…